What clinical trial evidence supports garaherb's safety and effectiveness for its approved indications?
Garadacimab (Andembry®, garadacimab‑gxii) is approved in several markets for prevention of hereditary angioedema (HAE) based on pivotal Phase 3 data from the global VANGUARD trial and supporting Phase...